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Antithrombin controls tumor 
migration, invasion and 
angiogenesis by inhibition of 
enteropeptidase
Ginés Luengo-Gil1,*, María Inmaculada Calvo2,*, Ester Martín-Villar2, Sonia Águila1, 
Nataliya Bohdan1, Ana I. Antón1, Salvador Espín1, Francisco Ayala de la Peña1, 
Vicente Vicente1, Javier Corral1, Miguel Quintanilla2 & Irene Martínez-Martínez1
Antithrombin is a key inhibitor of the coagulation cascade, but it may also function as an anti-
inflammatory, anti-angiogenic, anti-viral and anti-apoptotic protein. Here, we report a novel 
function of antithrombin as a modulator of tumor cell migration and invasion. Antithrombin inhibited 
enteropeptidase on the membrane surface of HT-29, A549 and U-87 MG cells. The inhibitory process 
required the activation of antithrombin by heparin, and the reactive center loop and the heparin 
binding domain were essential. Surprisingly, antithrombin non-covalently inhibited enteropeptidase, 
revealing a novel mechanism of inhibition for this serpin. Moreover, as a consequence of this inhibition, 
antithrombin was cleaved, resulting in a molecule with anti-angiogenic properties that reduced 
vessel-like formation of endothelial cells. The addition of antithrombin and heparin to U-87 MG and 
A549 cells reduced motility in wound healing assays, inhibited the invasion in transwell assays and 
the degradation of a gelatin matrix mediated by invadopodia. These processes were controlled by 
enteropeptidase, as demonstrated by RNA interference experiments. Carcinoma cell xenografts in 
nude mice showed in vivo co-localization of enteropeptidase and antithrombin. Finally, treatment with 
heparin reduced experimental metastasis induced by HT29 cells in vivo. In conclusion, the inhibition of 
enteropeptidase by antithrombin may have a double anti-tumor effect through inhibiting a protease 
involved in metastasis and generating an anti-angiogenic molecule.
Antithrombin is the main inhibitor of the coagulation cascade, but it has many other roles outside of hemostasis. 
Different studies have determined that antithrombin has an anti-inflammatory role by inhibiting nuclear fac-
tor KB signaling1,2. Moreover, results from clinical trials have supported the anti-inflammatory properties of 
antithrombin in patients with sepsis or disseminated intravascular coagulation3,4. Angiogenesis is another 
function identified for antithrombin5. However, only the latent and cleaved non-inhibitory conformations of 
antithrombin have anti-angiogenic properties. Thus, latent antithrombin reduces the vascularization of fibrosar-
coma6. The anti-angiogenic effects of cleaved and latent antithrombin have been compared to those of inhibitors 
such as endostatin and TNP-4707. Antithrombin may also function as an anti-viral molecule by altering the 
expression of several genes through different signaling pathways related to hepatitis C virus infection8. Moreover, 
antithrombin is involved in other cellular processes, such as apoptosis9, in which it exerts a protective role in 
mouse models of liver injury through inhibition of an unknown protease10. On the basis of all reported func-
tions, antithrombin can be defined as a pleiotropic protein. To date, antithrombin has not been associated with 
cancer, although proteolytic cascades are involved in tumorigenesis. Tumors grow and metastasize by means of 
various proteolytic activities in conjunction with intra- and inter-cellular signaling events. For example, to invade 
surrounding tissues and spread to distant locations, tumor cells exploit the activity of deregulated proteases to 
degrade and remodel intercellular junctions and extracellular matrix interactions. Members of the superfamily 
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of serine proteases known as type II transmembrane serine proteases (TTSPs) are among the enzymes deregu-
lated during tumor growth and progression. These TTSPs include TMPRSS2, corin, hepsin, enteropeptidase or 
TMPRSS15, matriptase, TMPRSS3, TMPRSS4, matriptase-2 and differentially expressed in squamous cell car-
cinoma gene 1 (DESC1)11. Recently, it has been shown that protein C inhibitor (PCI) and, to a lesser extent, 
antithrombin, may regulate the function of enteropeptidase. However, PCI does not inhibit enteropeptidase 
in vivo12. In this study, we characterized the antithrombin-mediated inhibition of enteropeptidase and investi-
gated the effects of antithrombin on tumor cell migration, invasion and angiogenesis. Besides, we assessed the 
effect of heparin treatment in metastasis in an in vivo mouse model.
Results
Antithrombin-mediated inhibition of enteropeptidase in cancer cells. We first analyzed entero-
peptidase gene (TMPRSS15) expression by qRT-PCR in the following cancer cell lines: MDA-MB231 (breast), 
MCF7 (breast), A549 (lung), U-87 MG (glioblastoma-astrocytoma), KATO-III (stomach), HT-29 (colon), and 
CACO-2 (colon). Only the HT-29, A549 and U-87 MG cell lines expressed TMPRSS15; therefore, they were 
selected for subsequent studies (Supplementary Fig. S1). None of these cell lines expressed antithrombin.
Next, we analyzed the effect of antithrombin on the activity of enteropeptidase in U-87 MG cells. We observed 
that antithrombin inhibited enteropeptidase activity in a concentration-dependent manner (Fig. 1A). This inhi-
bition was stimulated by the binding of heparin (Fig. 1B). Moreover, low molecular weight heparins (LMWH) 
stimulated antithrombin more efficiently than did unfractionated heparins or pentasaccharide (Fig. 1B). Figure 1 
shows the results obtained with U-87 MG cells, and experiments performed with HT-29 and A549 cells rendered 
similar results. Heparins had no effect on the activity of enteropeptidase (Fig. 1A, blank).
Antithrombin requires the following two functional domains to inhibit its target proteases in the coag-
ulation cascade: the residue R393 or P1 at the reactive center loop13,14 and the heparin binding domain15,16. 
To identify functional domains of antithrombin involved in enteropeptidase inhibition, two variants were 
tested. Antithrombin London lacks R393 at the reactive center loop, whereas antithrombin Toyama (R47C) 
has reduced heparin affinity. As shown in Table 1, both variants exhibited significantly impaired or abolished 
anti-enteropeptidase activity. Antithrombin London was completely unable to inhibit enteropeptidase. However, 
Figure 1. Enteropeptidase activity measured after solubilization from U-87 MG cells. (A) Residual activity 
of enteropeptidase after incubation of cells with different concentrations of antithrombin activated by 200 U/
mL low molecular weight heparin. (B) Effect of different heparins (UFH: unfractionated heparin; and LMWH: 
low molecular weight heparin) on the inhibition of enteropeptidase activity by antithrombin. The values are 
represented as the mean of three different experiments.
Vmax (mOD/min)
– 5.29 ± 0.2
LMWH 5.27 ± 0.3
AT 1.80 ± 0.3
AT + LMWH 0.20 ± 0.1
AT London + LMWH 5.06 ± 0.2
AT Toyama + LMWH 2.94 ± 0.2
Table 1.  Enteropeptidase activity using its chromogenic substrate after solubilization from U-87 MG cells. 
Enteropeptidase activity was evaluated after incubation of cells in the absence (− ) or presence of antithrombin 
(AT), AT activated by low molecular weight heparin (LMWH), AT London (Δ R393) in presence of LMWH, 
or AT Toyama (R47C) in presence of LMWH. The values are represented as the mean of three different 
experiments.
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antithrombin Toyama showed a reduced inhibitory effect because its reactive center loop is intact, but its activa-
tion by heparin is deficient. Table 1 shows the results obtained with U-87 MG cells. Experiments performed with 
HT-29 and A549 cells yielded similar results.
Antithrombin inhibition of purified enteropeptidase. The interaction between the protease and 
inhibitor was verified by SDS-PAGE. Intriguingly, although time course experiments were performed to follow 
the formation of covalent complexes, no bands were detected at the expected molecular mass (90 kDa approx-
imately) (Fig. 2, left panel). However, enteropeptidase activity was completely inhibited, because no hydrolysis 
of its chromogenic substrate was detected after incubation of the cells with antithrombin primed with LMWH. 
The resolution of these samples under non-reducing conditions provided an explanation: increasing amounts 
of cleaved antithrombin were detected in this time course incubation (Fig. 2, right panel). Cleaved antithrom-
bin usually migrates with lower mobility than intact protein17,18. Moreover, N-terminal sequencing of the band 
detected under non-reducing conditions after 1 hour of incubation with enteropeptidase confirmed that cleavage 
occurred at R393, the same residue recognized by the target enzymes of antithrombin involved in coagulation14. 
The cleavage at R393 may be detected as the C-terminal peptide of antithrombin remains bound after cleav-
age due to the disulfide bond between Cys247 and Cys43017. The cleavage of antithrombin was also verified in 
the supernatant of cells after 1 hour of incubation with antithrombin, as described in Materials and Methods 
(Supplementary Fig. S2). The formation of covalent complexes between enteropeptidase and antithrombin was 
not detected in these assays.
Enteropeptidase-mediated cleavage of antithrombin inhibits vessel formation by endothe-
lial cells. Because cleaved antithrombin has anti-angiogenic properties5, we investigated whether 
enteropeptidase-cleaved antithrombin was able to inhibit the formation of capillary-like structures by endothelial 
cells seeded in Matrigel-coated plates. The formation of enteropeptidase-cleaved antithrombin was first confirmed 
electrophoretically (Supplementary Fig. S3). Cleaved antithrombin (AT-EP-LMWH) inhibited vessel formation 
by EA.hy926 cells in Matrigel, whereas antithrombin, enteropeptidase or LMWH alone had no effect (Fig. 3A). 
This effect was also evaluated in a co-culture of EA.hy926 and U-87 MG cells. Although the number of vessels 
was reduced in comparison with those established by the endothelial cells on their own, addition of cleaved 
antithrombin (AT-LMWH-EP) resulted in the most significant reduction of vessel formation in the co-culture, 
confirming its anti-angiogenic effect (Fig. 3B, Supplemental Table S2). D,L-sulforaphane was used in this assay as 
a positive control. We also confirmed that EA.hy926 cells do not express enteropeptidase (Supplementary Fig. S4).
Antithrombin inhibits cancer cell migration and matrix degradation through enteropeptidase 
in cancer cells. Proliferation, migration and invasion are deregulated in cancer cells. We sought to inves-
tigate the potential role of the antithrombin-mediated inhibition of enteropeptidase in these three processes. 
Antithrombin had no effect on HT-29, A549 and U-87 MG cell proliferation regardless of whether it was activated 
by LMWH (Supplementary Fig. S5).
Next, we investigated the effect of antithrombin on cell migration using an in vitro wound healing assay19. 
A549 and U-87 MG cells were selected for these experiments because HT-29 had a reduced migration, even in 
the absence of treatment (Supplementary Fig. S6A). As shown in Fig. 4A,B and Supplementary Fig. S6B,C, A549 
and U-87 MG cells had an impaired ability to close the wound in the presence of either antithrombin or LMWH 
alone, but the effect on cell migration was more pronounced after combined treatment with antithrombin and 
LMWH. Downregulation of enteropeptidase expression by siRNA treatment reduced U-87 MG cell motility to 
the same extent as did antithrombin (Fig. 4C). These data are consistent with the involvement of enteropeptidase 
in tumor cell migration and with a heparin-enhanced inhibitory effect of antithrombin on cell migration, likely 
mediated by modulation of enteropeptidase activity.
Figure 2. Electrophoretic evaluation of the interaction between antithrombin and enteropeptidase at 
different incubation times. SDS-PAGE was run under reducing (+ DTT, r-SDS) and non-reducing conditions 
(−DTT, nr-SDS), and western blotting with immunodetection with antithrombin-specific antibody was 
carried out. An asterisk represents cleaved antithrombin. N indicates the electrophoretic mobility in SDS for 
antithrombin in its native conformation.
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Figure 3. Vessel formation by endothelial EA.hy926 cells and co-culture of EA. hy926 and U-87 MG 
cells on a Matrigel layer. Vessel formation was evaluated in different conditions after 24 hours of incubation. 
(A) Vessel formation by endothelial cells. (B) Vessel formation by co-culture of endothelial and U-87 MG 
cells. D,L-sulforaphane was used as positive control. Images were recorded with a Leica microscope at 5× , and 
ImageJ was used to analyze angiogenesis. Statistical analysis was carried out with a Mann-Whitney U test. Each 
condition was evaluated in octuplicate. * p < 0.05; * * p < 0.01. AT: antithrombin, LMWH: low molecular weight 
heparin; AT-EP-LMWH: mix of antithrombin, enteropeptidase and low molecular weight heparin after 24 hours 
of incubation, when enteropeptidase is completely inhibited and antithrombin is completely cleaved.
www.nature.com/scientificreports/
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Figure 4. Effects of antithrombin and heparin on cell migration of U-87 MG cells. Wound healing was 
evaluated after incubation of cells for 24 hours without treatment and after incubation with low molecular weight 
heparin (LMWH), antithrombin (AT) or antithrombin and LMWH in combination (AT-LMWH). (A) Microscope 
images of cells 24 hours after the wound with the pipette tip. (B) Percentage of wound confluence under the 
different conditions. (C) Percentage of wound confluence under the different conditions in TMPRSS15-silenced 
cells. Each condition was evaluated in triplicate, and five different images were processed for each different assay; 
* p < 0.05; * * p < 0.01. Images were recorded with a Leica microscope at 5× , and Image J was used to analyze 
migration. Statistical analysis was carried out with a Mann-Whitney U test.
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We also evaluated the role of enteropeptidase on invasion and the effect of antithrombin during this process. 
A Matrigel invasion assay was performed with U-87 MG and A549 cells (Fig. 5 and Supplementary Fig. S7). 
As shown in the Figures, a significant reduction of invasiveness was observed when cells were treated with 
antithrombin activated by LMWH. Additionally, it has previously been demonstrated that invadopodia, ventral 
actin-rich plasma membrane protrusions involved in tumor cell invasion, contain metalloproteases and serine 
proteases that are responsible for matrix degradation20. Because U-87 MG cells are able to form invadopodia, we 
also analyzed the effect of antithrombin on the formation and activity of these structures. Interestingly, treatment 
with antithrombin significantly impaired the ability of the cells to degrade gelatin without affecting the forma-
tion of actin puncta on the basal surface of U-87 MG cells, an effect that was enhanced by LMWH (Fig. 6A,B). 
Knockdown of enteropeptidase significantly reduced gelatin degradation (Fig. 6C). Interestingly, treatment 
of enteropeptidase-downregulated cells with antithrombin plus LMWH further reduced gelatin degradation 
activity. This result might suggest that other antithrombin target proteases are involved in addition to entero-
peptidase, because invadopodia contain a machinery of proteases responsible for complete extracellular matrix 
degradation20.
Antithrombin and enteropeptidase co-localize in tumors induced in vivo. To ascertain whether 
antithrombin and enteropeptidase interact in vivo, we analyzed their co-localization in tumors induced by injec-
tion of HT-29 and A549 cell lines into nude mice. Only these cell lines were used because U-87 MG cells were 
not tumorigenic (Supplementary Table S1). As shown in Fig. 7, mouse antithrombin co-localized with entero-
peptidase in tumor cells, indicating a potential interaction between both molecules; antithrombin may extrav-
asate to the tumor tissue (Supplementary Fig. S8). Although co-localization of both proteins is not sufficient to 
support the anti-tumor role of antithrombin, the colocalization of both proteins in vivo strongly suggests that 
antithrombin-mediated inhibition of enteropeptidase may be physiologically relevant.
Heparin treatment reduces HT29-induced experimental metastasis in vivo. Since the in vitro 
results showed that antithrombin may have a role in the inhibition of the migration and invasion while the effect 
on proliferation was negligible, we studied the effect of LMWH on experimental metastasis using an in vivo ani-
mal model. HT29 cells expressing luciferase were injected into the tail vein of athymic nude mice. In a group of 
animals, a single dose of LMWH was intraperitoneally inoculated 30 min before tumor cell injection, while a sec-
ond group of mice (control) received the vehicle (PBS). In both groups, only 5 out of 10 mice developed detectable 
metastases the third week post-injection, and the number of animals with metastases increased to 6 the fourth 
week (Supplementary Fig. S9). Nevertheless, metastatic lesions of mice treated with LMWH had a reduced area 
compared to control mice, as shown by measuring the intensity of luminescence (Fig. 8A–C). These differences 
were statistically significant at week 3 post-injection, but although a decreased intensity of luminescence was still 
observed in the LMWH group significance was lost at week 4 (Fig. 8C). The presence of metastatic cells in liver 
and backbone was detected by luciferase immunostaining of histological sections (Fig. 8D). The staining was only 
detected in sections corresponding to control mice, maybe due to undetectable micrometastasis in the LMWH 
group.
Discussion
Enteropeptidase is a serine protease that belongs to the type II transmembrane serine protease superfamily. It 
has been reported that the members of this superfamily are involved in the progression of some tumors21–23, 
although the physiological function of enteropeptidase is the conversion of zymogens into active proteases for 
food digestion24. Nevertheless, enteropeptidase has never been implicated in tumorigenic processes. Here, we 
confirm the expression of enteropeptidase in cell lines from colorectal, glioblastoma and lung cancer origins 
and, to our knowledge, demonstrate for the first time the direct role of enteropeptidase in tumor migration and 
matrix degradation. Our results show that the addition of antithrombin and especially antithrombin activated by 
LMWH, delayed cell migration and reduced matrix degradation of cells expressing enteropeptidase. These two 
processes (cell migration and matrix degradation) are key steps in facilitating tumor invasion and metastasis, and 
appear to be controlled by enteropeptidase as demonstrated by silencing its expression. In fact, treatment with 
LMWH was able to reduce the metastatic ability of tumor cells expressing enteropeptidase in an in vivo animal 
model. It has been shown that enteropeptidase may be inhibited by another serpin, PCI12. However, it could not 
be demonstrated that this inhibition occurs in vivo because the two proteins (PCI and enteropeptidase) did not 
co-localize in the tissue. Our results show that antithrombin might function as an in vivo inhibitor of enteropep-
tidase in pathological conditions, in which the two proteins may be in contact, thus increasing the likelihood of 
the interaction, although there should be heparin present. Nevertheless, as with antithrombin, PCI could also 
extravasate and inhibit enteropeptidase in tumors, being both serpins regulators of enteropeptidase function.
The inhibition of enteropeptidase by antithrombin appears to be accelerated by heparin. The fact that pen-
tasaccharide and LMWH provoked a stronger inhibition of enteropeptidase by antithrombin than did unfrac-
tionated heparins indicated that this process depends on the allosteric activation of antithrombin and that long 
chain heparins may interfere with the inhibition of enteropeptidase. Moreover, the inhibition of enteropeptidase 
requires the two functional domains of antithrombin (the RCL and the heparin binding domain)13–16. However, 
the results obtained when cells were incubated with antithrombin and the different heparins, indicate that, in this 
process, LMWH is more efficient.
The anti-tumor effect of LMWH has been extensively evaluated. Clinical trials have demonstrated its effect 
on increasing the survival of cancer patients with and without venous thrombotic disease, independently of its 
effect on coagulation25–28. However, additional trials are required to define the tumor types, disease stages and 
dosage schedules that provide the greatest survival benefit29. There are many biological roles of LMWH; it can 
block several crucial events during the tumorigenic process30,31. A critical event in invasion and metastasis is 
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Figure 5. Effects of antithrombin and heparin on invasion by a transwell assay. Cell invasion was evaluated 
after incubation of U-87 MG cells for 6 hours under the following conditions: no treatment, incubation with 
low molecular weight heparin (LMWH), antithrombin (AT) or incubation with antithrombin and LMWH in 
combination (AT-LMWH). (A) Microscope images of cells invaded after 6 hours of incubation. (B) Percentage 
of cells invading under the different conditions. Each condition was evaluated in triplicate, and three different 
images were processed for each different assay; * p < 0.05; * * p < 0.01. Images were recorded with a Leica 
microscope at 5× , and Image J was used to analyze cells that had migrated. Statistical analysis was carried out 
with a Mann-Whitney U test.
www.nature.com/scientificreports/
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the degradation of extracellular matrix components, such as collagen, laminin, fibronectin and proteoglycans32. 
Tumor cells are able to break down the extracellular matrix by secretion of metalloproteases, serine proteases, 
cysteine proteases and endoglycosidases, such as heparanase33, whose function may be impaired by LMWH34. 
However, some of the anti-tumor effects of heparins, the main cofactor of antithrombin, might also be mediated 
by the inhibitory function of antithrombin. In fact, the inhibitory effect of antithrombin on matriptase, a trans-
membrane serine protease involved in matrix remodeling, has been previously reported35. Although proliferation 
of cells expressing enteropeptidase is not affected by treatment with antithrombin, cell migration and matrix 
Figure 6. Effects of antithrombin and heparin on invadopodia degradation of gelatin coated coverslips. 
(A) Representative micrographs of U-87 MG cells on a rhodamine-gelatin matrix. Cells were incubated without 
treatment or with low molecular weight heparin (LMWH), antithrombin (AT) and antithrombin activated by 
LMWH (AT-LMWH). Invadopodia were identified by colocalization of actin punctae over or close to areas 
of degraded matrix, which are indicated with a white arrow. (B) Quantification of invadopodia-mediated 
gelatin degradation of cells under the different treatments. (C) Quantification of invadopodia-mediated gelatin 
degradation of cells transfected with a scrambled siRNA or the specific silencer for TMPRSS15 gen (SiEP) with 
or without treatment with AT in combination with LMWH. Each condition was assayed in triplicate, and up 
to twenty-five different images were processed for each condition; * p < 0.05; * * p < 0.01. Images were acquired 
with a Nikon 90i microscope at 60× , analyzed with Fiji software to calculate gelatin degradation and statistical 
analysis was carried out with a Mann-Whitney U test.
www.nature.com/scientificreports/
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degradation (key steps for tumor invasion) were significantly inhibited. Moreover, the reduction in the migration 
and invasion of the cells was exacerbated when they were incubated with activated antithrombin. These events 
may indicate that some of the anti-tumor effects attributed to heparins might be mediated by the function of 
antithrombin. Our in vivo results demonstrated that treatment with LMWH, previously to the injection of the 
tumor cells expressing enteropeptidase into the tail vein of mice, reduced the extent of metastatic lesions in com-
parison to those treated with vehicle. However, metastatic colonies were able to grow also in mice treated with 
LMWH. This is in concordance with the ABEL study36, in which authors concluded that prophylactic treatment 
with LMWH improved overall survival and disease free survival only in patients with limited-stage small cell lung 
cancer. Recently, it has been published that over-expression of the serpin member heparin co-factor II (HCII) 
in non-small cell lung cancer is associated with increased metastasis and that binding of heparin blocks the 
pro-metastatic action of HCII37. Therefore, the action of LMWH in impairing tumor cell migration/invasion and 
metastasis, as shown in this paper, might be mediated at least in part by HCII or by the effect of LMWH on other 
proteins involved in tumor cell growth and metastasis, such as the receptor for advanced glycation end-products 
axis or on the up-regulation of PI3K by HCII37,38. Nevertheless, we speculate that patients with tumors expressing 
enteropeptidase may benefit from the treatment with heparins, and we cannot exclude that antithrombin might 
also inhibit other proteases involved in tumor progression.
In this work, we demonstrated a unique property of the inhibition of enteropeptidase by antithrombin. The 
interaction between enteropeptidase and antithrombin did not involve the formation of covalent complexes. An 
unexpected consequence of enteropeptidase inhibition by antithrombin was angiogenesis inhibition. Our results 
showed that, after interaction with enteropeptidase, antithrombin remained in a cleaved conformation. This result 
is especially relevant because an anti-angiogenic role has been attributed to the cleaved protein5, and we showed 
that antithrombin, after incubation with enteropeptidase, inhibited vessel formation of endothelial cells even in 
co-culture with tumor cells. The enteropeptidase-dependent antiangiogenic effects of antithrombin might be 
especially relevant in the setting of the tumor models glioblastoma, lung cancer and colorectal cancer. All of these 
are prevalent tumors and show prominent angiogenic activation; consequently, they are usually treated with 
antiangiogenic drugs such as bevacizumab. The antiangiogenic therapeutic strategy leads to consistent improve-
ments in progression free and overall survival in patients with advanced disease bearing any of these tumors, in 
clear contrast with the effects of the same drug in other neoplasms39–41. No data are available on enteropeptidase 
expression in these neoplasms in a clinical setting, but our results warrant further work to delineate its potential 
in tumor progression and, especially, to better define the role of antithrombin, enteropeptidase and heparin in 
their angiogenic behavior.
Figure 7. Co-localization of enteropeptidase and antithrombin in human xenograft tumors surgically 
removed from nude mice. HT-29 and A549 tumor cells were subcutaneously injected in the two flanks of nude 
mice and removed when they reached approximately 1 cm in diameter. Immunohistofluorescence of slides from 
tumors was performed by incubating with Alexa Fluor 549 and Alexa Fluor 488 antibodies for detecting the 
primary antibodies specific to enteropeptidase and antithrombin, respectively. Some of the areas of co-localization 
are indicated with white arrows.
www.nature.com/scientificreports/
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Figure 8. Low molecular weight heparin reduces metastatic potential in vivo. (A) Representative whole 
body bioluminescence images of mice showing metastatic colonies at week 0, 1, 2, 3 and 4 after injection into 
the tail vein of HT-29 cells and previous treatment with 100 U Low molecular weight heparin (LMWH) or 
vehicle (PBS). (B) Bioluminescence imaging assay of tumors in mice at week 0, 1, 2, 3 and 4 post treatment and 
injection of cells. Mean bioluminescence counts ± SEM (n = 5). (C) Quantification of metastasis as assessed 
by bioluminescence measurements at week 3 and week 4 from the tail vein injection of HT-29 cells after 
previous treatment of mice with PBS or LMWH. Statistical analysis was carried out with the Student’s t-test. 
(D) Immunological detection of luciferase protein expression in liver and backbone by confocal microscopy. 
Histological sections of two control mice treated with PBS showing HT29-CMV-luciferase cells invasion. Signal 
of secondary antibody (negative control) is also shown (left panel). Scale bar: 100 μ m
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In summary, to our knowledge, here we provide the first demonstration that antithrombin may have an 
anti-tumor effect through a double mechanism, inhibition of a protease involved in tumor migration and invasion 
and generation of anti-angiogenic cleaved antithrombin.
Materials and Methods
Cell lines. MDA-MB-231, MCF7, KATO III, and Caco-2 were obtained from the Service of Cell Culture, 
Investigation Support Service (S.A.I, University of Murcia). U-87 MG and A549 were kind gifts from Dr. M.I. 
Martínez-Lacaci (IMIB-Arrixaca, Murcia, Spain) and Dr. P. Martín-Duque (Francisco de Vitoria University, 
Madrid, Spain), respectively. The human EA. hy926 endothelial cell line was a kind gift from Dr. C.-J. S. Edgell 
(University of North Carolina, USA). All cell lines were cultured following the ATCC animal cell culture guide 
and using recommended culture mediums. All cell lines were tested for mycoplasma contamination using Venor® 
GeM Classic Mycoplasma PCR Detection Kit (Minerva Biolabs, Berlin, Germany), and authentication was deter-
mined by Short tandem repeat profiling42.
qRT-PCR. The expression of TMPRSS15 gene in all cell lines was determined by qRT-PCR using SYBR Premix 
Ex Taq II (Takara) in a LightCycler480 (Roche), following the manufacturer’s indications. The primers used for 
the amplification of TMPRSS15 gene and beta-actin, as a reference gene, are described in the Supplementary 
Information section.
Incubation with antithrombin and enteropeptidase solubilization of cell lines. Antithrombin 
(150 ng/μ L) and/or heparin (200 U/mL) were added to the cells (HT-29, U-87 MG and A549), which were then 
incubated at 37 °C. After 1 hour of incubation, medium was withdrawn, and cells were washed three times with 
PBS.
The cells were detached by adding a lysis buffer (20 mM Tris HCl, 1% Triton X-100, pH 7.5) and using scrapers. 
Then, cells were centrifuged at 13684 g for 10 min at 4 °C. The supernatant was recovered and then used for the 
determination of enteropeptidase activity. To determine enteropeptidase activity, Z-Lys-SBzl was used at 200 μ M 
in TCNB buffer (50 mM Tris, 0.15 M NaCl, 10 mM CaCl2, and 0.05% Brij-35,pH 7.5) containing 200 mM Ellman’s 
reagent (5,5′ -dithiobis-(2-nitrobenzoic acid)). The absorption was recorded at 405 nm for 60 min to assess the 
activity of enteropeptidase.
In vitro inhibition of enteropeptidase by antithrombin. Formation of covalent complexes between 
antithrombin and enteropeptidase (Sigma, Madrid, Spain) was evaluated by adding an excess of enteropeptidase 
(150 μ M) to 5 μ M of antithrombin and incubating the complex at different times (0, 15, 30, 45 and 60 min) at 
37 °C. Complexes were evaluated by 8% SDS-PAGE under reducing and non-reducing conditions, as described 
elsewhere43.
To evaluate which functional domains of antithrombin are required for the inhibition of enteropeptidase, two 
different antithrombin mutants were used, and enteropeptidase activity was measured (antithrombin London 
and antithrombin Toyama). Mutagenesis of plasmid containing cDNA coding for antithrombin, transfection of 
HEK-EBNA cells and purification of variants were carried out as previously described13,15.
Edman sequencing. Edman sequencing of the antithrombin cleaved by enteropeptidase was performed 
under non-reducing conditions with Applied Biosystems Procise 494 equipment (Foster City, CA, USA). Because 
of the presence of a C-terminal disulfide bond between Cys247 and Cys430, cleavage at the reactive center loop of 
antithrombin is detected as the cleaved peptide remains bound17,18.
Effect of antithrombin on vessel formation of endothelial cells EA. hy926 and in co-culture with 
U-87 MG cells. Cells were added to a 96-well plate (15000 cells in 100 μ L of medium deprived of fetal bovine 
serum to each well) previously treated with 9 μ L of Matrigel. The conditions studied were as follows: 1) 10 μ M 
D,L-sulforaphane; 2) 2.5 μ M antithrombin, 2.5 μ M enteropeptidase, and 200 U/mL LMWH, previously incubated 
together at 37 °C for 24 hours; 3) 2.5 μ M antithrombin; 4) 2.5 μ M enteropeptidase; 5) 200 U/mL LMWH. Each 
condition was assayed in eight different wells. D,L-sulforaphane was used as a positive control in this assay44. 
Co-culture of EA. hy926 and U-87 MG cells was also assayed to determine the effect on vessel formation. As 
described, 15000 cells from each of the cell lines were added to the 96-well plate under the same conditions as 
described above. The conditions studied were as follows: 1) 10 μ M D,L-sulforaphane; 2) 2.5 μ M antithrombin, 
2,5 μ M enteropeptidase, and 200 U/mL LMWH, previously incubated together at 37 °C for 24 hours; 3) 2.5 μ M 
antithrombin; and 4) 200 U/mL LMWH. Each condition was assayed in eight different wells.
The second condition of both assays generated cleavage of antithrombin by enteropeptidase, as verified by 8% 
SDS-PAGE under non-reducing conditions and silver staining. The lengths of endothelial tubes formed in each 
well was quantified from captured images using Angiogenesis Analyzer for ImageJ when endothelial cells were 
assayed alone and manually using segmental lines and setting scale in ImageJ when co-culture was analyzed. 
Statistical analysis was performed with a Mann-Whitney U test in IBM SPSS Statistics 21 software.
Silencing of TMPRSS15. U-87 MG cells were grown in a humidified atmosphere with a 5% CO2 con-
centration. ON-TARGETplus SMARTpool siRNAs against TMPRSS15 and control siRNA were obtained from 
Dharmacon (GE Dharmacon, Barcelona, Spain). siRNA transfections were performed using PepMute trans-
fection reagent (SignaGen, MD, USA). Silencing rates were approximately 80% after two days of transfection 
(Supplementary Fig. S10).
Proliferation and wound healing assays. After 24 hours, cell proliferation was assessed using XTT 
according to the manufacturer’s protocol (ATCC, Manassas, VA, USA). Six replicates for each condition were 
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examined. The three following conditions were studied in comparison with cells without any treatment: 1) 2.5 μ M 
antithrombin, 2) 200 U/mL LMWH, and 3) 2.5 μ M antithrombin and 200 U/mL LMWH. Absorbance values at 
450 nm (corrected at 690 nm) were measured using a microplate spectrophotometer.
For the wound healing assay, cells were cultured as confluent monolayers, synchronized in 1% FBS for 24 h, 
and wounded by removing a 300–500 μ m-wide strip of cells across the well with a standard 200 μ l pipette tip. 
Wounded monolayers were washed twice to remove non-adherent cells. The following three conditions were 
studied in comparison to cells without any treatment: 1) 2.5 μ M antithrombin, 2) 200 U/mL LMWH, 3) 2.5 μ M 
antithrombin and 200 U/mL LMWH. The same experiment was carried out with TMPRSS15-silenced U-87 MG 
cells in the absence and presence of the combination of 2.5 μ M antithrombin and 200 U/mL LMWH. Wound 
healing was quantified using ImageJ software as the median percentage of the remaining cell-free area compared 
to the area of the initial wound. Statistical comparisons were performed using the Mann–Whitney U test.
Matrigel invasion assay and invadopodia degradation of gelatin coated coverslips. Matrigel 
invasion assays were performed at 37 °C for 6 hours using 24-well transwell inserts coated with Matrigel 
(BD Biosciences, Madrid, Spain). U-87MG and A549 cells 200000 suspended in 400 μ L serum-free medium 
were seeded into the upper chamber and 500 μ L serum-supplemented medium was added in the lower 
chamber. The following three treatments were analyzed in comparison to cells without treatment: 1) 2.5 μ M 
antithrombin, 2) 200 U/mL LMWH, and 3) 2.5 μ M antithrombin and 200 U/mL LMWH. Cells that migrated 
and invaded through the membrane were counted after fixing and staining with crystal violet. Images were 
analyzed with Fiji software and processed with Adobe Photoshop. Statistical significance was analyzed by the 
Mann–Whitney U test.
For evaluation of invadopodia degradation, gelatin matrix was prepared by mixing 0.2% gelatin and 
Rhodamine (Invitrogen, Life Technologies, Madrid, Spain) at a 1:55 ratio in 61 mM NaCl, 50 mM sodium boro-
hydrate and dialyzed overnight in PBS. Coverslips were first coated with this mix and then fixed with 0.5% glu-
taraldehyde for 15 min. After coating, coverslips were washed with PBS. For the degradation assay, U-87 MG 
cell suspensions were plated on top of these coated coverslips for 24 hours in the presence of 25 ng/mL hGF 
(Sigma-Aldrich, Madrid, Spain). The same three conditions as above were studied in comparison to cells without 
any treatment, as follows: 1) 2.5 μ M antithrombin, 2) 200 U/mL LMWH, and 3) 2.5 μ M antithrombin and 200 U/
mL LMWH. The same experiment was carried out with silenced TMPRSS15 cells in the absence or presence 
of the combination of 2.5 μ M antithrombin and 200 U/mL LMWH. Immunofluorescence analysis was carried 
out after fixing the cells with 3.7% formaldehyde and incubation with phalloidin, Alexa Fluor 488 and DAPI 45. 
Images were taken with a Nikon 90i microscope at 60× , analyzed with Fiji software and processed with Adobe 
Photoshop45. Cells that degraded gelatin were scored as positive, and more than 100 random selected cells were 
quantified. The percentage of cells with invadopodia-mediated degradation was plotted and statistical significance 
was analyzed by the Mann–Whitney U test. Global association was also statistically analyzed by Kruskal-Wallis 
test.
Carcinoma cell xenografts in nude mice and immunodetection of antithrombin and enteropep-
tidase in tumors. Described in detail in Supplementary Materials and Methods.
Experimental metastasis in nude mice and treatment with heparin. Animals were kept in venti-
lated rooms under lighting (12-h light, 12-h dark cycle) and temperature controlled conditions, and allowed feed 
and water ad libitum. All experimental procedures were conducted in compliance with 2010/63/UE European 
guidelines.
5 × 105 Colon cancer cells (HT-29), infected with lentiviral expression particles for luciferase 
(CMV-Luciferase firefly, from Amsbio Abingdon, UK), were injected into the tail vein of 6-weeks old nu/nu mice 
30 minutes after intraperitoneal injection of 100 units of LMWH (n = 10), or control PBS (n = 10), under anes-
thesia (Isofluorane). Each mouse was imaged periodically, using an IVIS Lumina 2 imaging system (Xenogen, 
Alameda, CA) after retro-orbital injection of 3 mg luciferin (Goldbio., St. Loius, MO, USA) in 100 μ l of DPBS, 
under anesthesia, using 5 min, 2 min and 30 sec exposure time. After 4 weeks, mice were euthanized and pieces 
of liver and backbone were excised.
Immunohistochemical analysis. For immunolocalization of luciferase in histological sections, pieces 
of liver and backbone were fixed in pH 7.0 buffered 3.7% formaldehyde and processed for histology. Hydrated 
histological sections were stained with goat pAb against luciferase (Novus Biologicals, Littleton, CO), after per-
meabilization in 0.1% Triton X-100, antigen retrieval in citrate buffer (0,01 M, pH6), and blocking in 0.5% BSA. 
The immunofluorescent signal of liver sections was revealed using donkey anti goat IgG secondary antibody, 
Alexa Fluor 546-coupled. The primary antibody signal in backbone sections was amplified using donkey anti goat 
IgG, HRP coupled, secondary antibody and TSA Plus Cyanine 3 (Perkin Elmer, Massachusetts, USA), follow-
ing the manufacturer’s instructions. In both cases, cells nuclei were counterstained with DAPI. Histological sec-
tions were also stained with standard haematoxylin-eosin for routine evaluation of tissue morphology. Confocal 
laser-scanning microscopy was performed in a Leica TCS-SP2 microscope (Leica Microsystems, Heidelberg, 
Germany). Images were acquired using a 63× (NA 1.32) oil-immersion objective and assembled using Leica 
Confocal Software 2.0.
Ethic Statement. The ethical committee “CEIC Hospital General Universitario José María Morales 
Meseguer” approved the experimental protocols included in this paper.
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